Merit Medical Systems (MMSI) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $339.8M, up 7.8% year-over-year, with constant currency revenue up 7.9% and organic constant currency revenue up 5.7%.

• Non-GAAP Q3 net income increased 23.5% to $51.2M, with EPS up 21.1% to $0.86; GAAP EPS was $0.48, up 8.0%.

• Free cash flow for the first nine months of 2024 was $120M, up 116% year-over-year.

• Announced acquisition of Cook Medical's lead management portfolio for $210M, expected to close Nov 1, 2024, and add $40M annualized revenue starting FY2025.

• Completed acquisition of EndoGastric Solutions assets in July 2024, contributing to endoscopy growth.

Financial highlights

• GAAP gross margin for Q3 2024 was 46.4% (up from 45.1%); non-GAAP gross margin was 50.9% (up from 49.8%).

• Q3 net income was $28.4M ($0.48/share), up from $25.8M ($0.44/share) in Q3 2023.

• Q3 non-GAAP operating margin was 19.2% (up from 17.4%); GAAP operating margin was 11.0%.

• Cash and equivalents at quarter-end were $523.1M; total debt $770.5M; net leverage ratio 2.08x.

• Operating cash flow for the first nine months was $152.1M; capital expenditures were $31.7M.

Outlook and guidance

• Updated 2024 revenue guidance: $1.344–$1.352B, up 6.9%–7.6% year-over-year; non-GAAP EPS guidance raised to $3.33–$3.38, up 17%–19%.

• Cardiovascular segment expected to grow 5%–6.2%; endoscopy segment 49%–52%.

• Guidance includes projected impacts from the Cook Medical acquisition, expected to close Nov 1, 2024.

• Free cash flow guidance increased to ~$150M for 2024.

• Management targets sustainable growth and profitability through 2026 via "Continued Growth Initiatives."